Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

California Group To Boost HIV Prevention Measures In Adult Film Industry
The California-based clinic Adult Industry Medical Healthcare Foundation (AIMHF), which serves the adult film industry, said on Monday it will boost its HIV prevention measures by urging the industry to use an online database to verify that employees have recently been tested for HIV, the Los Angeles Times reports. The industry currently requires that workers be tested every 30 days. Los Angeles County health officials recently reported that there had been 16 unpublicized cases of HIV in adult film workers in the county since 2004 after news emerged last week that an adult film actress tested positive for HIV (Yoshino, Los Angels Times, 6/15).
generic viagra online
Rigel's R788 Evaluated In Phase 2 Trial In Multiple Cancers
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. This open-label, single arm clinical trial will include patients with advanced colorectal, thyroid, non-small cell lung, hepatocellular, head and neck, or renal cell cancers who have failed to respond to at least one line of therapy.
News of the day
Vetericyn Inc. Launches Equine Wound & Infection Product Utilizing FDA-Cleared Technology
Vetericyn Inc., a California-based animal healthcare company, has announced the launch of its new Vetericyn™ equine product, available in a 16-ounce trigger spray for horses. Vetericyn™ utilizes an FDA-cleared technology that has been used to successfully treat over one million human patients without a single serious adverse effect. Now, the innovative topical wound-care product is available to the animal healthcare market.
Health Insurance

Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger. Levonorgestrel is the generic equivalent to Duramed Pharmaceuticals" PLAN B(R), which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure. This product is approved for prescription use only. The Company intends to market the product under the trade name Next Choice(TM) and plans to launch the product shortly. For the 12-months ending March 2009, PLAN B(R) had total U.S. sales of approximately $123 million, of which approximately ten percent are attributable to prescription sales, according to IMS sales data. PLAN B(R) over-the-counter (O.T.C.) new product exclusivity expires on August 24, 2009. About Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women"s Health and Nephrology/Medical. Forward-Looking Statement Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson"s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson"s current expectations depending upon a number of factors affecting Watson"s business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson"s products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson"s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson"s Annual Report on Form 10-K for the year ended December 31, 2008. PLAN B(R) is a registered trademark of Women"s Capital Corporation, a subsidiary of Duramed Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009